BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 2294263)

  • 1. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
    Sarosdy MF; Hudnall CH; Erickson DR; Hardin TC; Novicki DE
    J Urol; 1989 Mar; 141(3):551-3. PubMed ID: 2645420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
    Kattan S; Collins JP; Mohr D
    Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
    Waldhauser M; Schramek P
    J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Zaher TF
    Int Urol Nephrol; 1998; 30(2):193-6. PubMed ID: 9607891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
    Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
    Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of impotence by intrapenile injections of papaverine and phenoxybenzamine: a double blind, controlled trial.
    Keogh EJ; Earle CM; Carati CJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR
    Aust N Z J Med; 1989 Apr; 19(2):108-12. PubMed ID: 2669713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.
    Chen JK; Hwang TI; Yang CR
    Br J Urol; 1992 Apr; 69(4):404-7. PubMed ID: 1581812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of prostaglandin E1 for papaverine-failed erections.
    Reiss H
    Urology; 1989 Jan; 33(1):15-6. PubMed ID: 2911923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients.
    Mahmoud KZ; el Dakhli MR; Fahmi IM; Abdel-Aziz AB
    J Urol; 1992 Mar; 147(3):623-6. PubMed ID: 1538443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological erection program using prostaglandin E1.
    Gerber GS; Levine LA
    J Urol; 1991 Sep; 146(3):786-9. PubMed ID: 1875494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.